As the only hospital reference lab integrated with a world-renowned academic healthcare institution, Mayo Clinic Laboratories fuses diagnostic testing innovation with a 150-year history of patient-focused care. In that tradition, we advocate for delivering care as close to the patient as possible, offering a vast menu of esoteric and advanced assays that complements, rather than competes with, local care delivery.
Our proactive consultative approach helps hospital laboratories uncover their financial potential and improve profitability while keeping patient care as the focus. Through synergistic relationships, we equip lab teams and hospital executives with tailored tools and strategies to expand laboratory capabilities and improve efficiencies. This supports the growth of the lab, and the health system, into new areas of diagnostic care.
“Our business model and our mission are to support the local care of patients. We work with hospitals and hospital laboratories to help them insource testing they should to take care of their patients, and give them access to those more uncommon tests we're developing within our practice.”
William Morice II, M.D., Ph.D., President and CEO, Mayo Clinic Laboratories
Our difference
The latest
An order-entry, clinical decision support tool developed by physicians and scientists at Froedtert and the Medical College of Wisconsin (MCW) for clinicians within the healthcare system who order autoimmune and paraneoplastic antibody panels has significantly improved test utilization, resulting in a 28% reduction in monthly test volumes of impacted tests.
With many organizations using a digital-first approach, it is easy to assume that is always the best option. But is it? And what about for your laboratory outreach program? Laboratories should consider these seven S’s when deciding whether connectivity will align with the goals of their outreach programs.
Since 1992, cases of colorectal cancer have been on a slow decline, yet 52,550 people died from it in 2023. At Mayo Clinic, a cutting-edge menu of both germline (inherited genetic alterations) and somatic (tumors due to non-inherited genetic alterations) testing are two critical tools helping to improve targeted treatments for colorectal and other common gastrointestinal cancers.
Dr. Linda Hasadsri’s firsthand encounter with the genetic tests she’s helped develop has provided rare insight into testing quality and implications, enhancing their ability to advocate for the value of testing and infusing their work with deep empathy.
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton. They discuss how an outreach program can work with its customers on process improvements by using periodic visits and data-driven discussions.
Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.
Depending on the types of specimens that are referred to the outreach laboratory, there may be an opportunity to share a customer performance update report with the client so that they can align with, or even develop their own laboratory continuous improvement initiatives. This data-sharing provides valuable metrics and allows the client an opportunity to improve their services. Through identifying issues and working together to resolve them, the customer and the laboratory are aligned in their mission of putting the needs of the patient first.
Prevented from providing testing services to its community members due to a non-compete agreement with a national laboratory, Kootenai Health laboratory leaders deepened their relationship with Mayo Clinic Laboratories, receiving tactical support and guidance to launch an in-house reference lab just days after the non-compete agreement expired.
Multiple doctors and multiple examinations could not figure out why Lauri Sieben had spent much of her life “never feeling quite right” physically. Fortunately for Lauri, that changed after her daughter Christy began working as a genetic counselor in Mayo Clinic’s Molecular Technologies Laboratory. After seeing similarities between the patient testing she was performing for the lab and the physical symptoms being experienced by her mom, Christy took a leading role in getting Lauri to undergo molecular and biochemical testing at Mayo Clinic. The results of that testing not only provided much-needed answers, but a promising path forward for Lauri.
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, talks with Erin Hoffman, division director of hospital sales and services at Mayo Clinic Laboratories. They discuss the value of the hospital laboratory, the challenges and opportunities facing community labs today, and how to have impactful conversations with hospital leadership.
In a competitive outpatient testing market, choosing a laboratory is discretionary. With the goal of becoming the laboratory of choice for discretionary outpatient testing, it no longer matters if it is called “inreach” or “outreach.” While these terms may be decent descriptors for a process, they do not begin to describe the true value of this critical community laboratory activity. The value of a laboratory outreach program spans all areas of relevance for a health system. Through supporting clinical integration and community health initiatives, the laboratory is a critical element, enabled and supported by a successful outreach activity.
On the brink of losing her battle with acute myeloid leukemia, Shannon Camlek arrived at Mayo Clinic as a last hope. Her chances didn’t look good, but with the help of specialized genetic testing, particularly FISH (fluorescence in situ hybridization) studies, doctors were able to detect the specific gene mutations responsible for her symptoms and disease. The test results also helped Shannon’s care team target her treatment accordingly, and finally put an end to what Shannon likens as starring in her own personal horror movie while in search of hope and healing.
Endometrial cancer affects thousands annually and ranks as the fourth most common cancer among women in the United States. At the forefront of innovative discoveries in endometrial cancer diagnostics are Mayo Clinic's Department of Laboratory Medicine and Pathology consultants. Sounak Gupta, M.B.B.S., Ph.D., vice chair of Oncology Practice for the Division of Laboratory Genetics and Genomics; Maryam Shahi, M.D., senior consultant for Anatomic Pathology; and Andrea Mariani, M.D., M.S., division chair of Gynecologic Surgery, explore the critical significance of molecular profiling and collaborative efforts driving these innovations, highlighting Mayo Clinic’s revolutionary influence on patient care.